All News
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Read Article
Cardiovascular Risk in Cutaneous Lupus Erythematosus
A retrospective study of cutaneous lupus erythematosus (CLE) patients finds an increased risk of atherosclerotic cardiovascular disease (ASCVD) on par with systemic lupus patients.
Read Article
Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
Childhood Maltreatment and the Risk of Rheumatic Diseases
EurekAlert!
A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.
Read Article
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.
Read Article
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - New Palmoplantar Psoriasis and PsA
New Onset Palmoplantar PsO and PsA - what are the options?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/HZZuDvga58 https://t.co/wWKhnIECwB
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/xUPXA79weS https://t.co/eUeemqovv8
Links:
Dr. John Cush RheumNow ( View Tweet)
Participation is Up! (1.31.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. We also have two call-in cases on "Ask Cush Anything".
https://t.co/kxMkDW5X8c https://t.co/AjIuNzk7co
Dr. John Cush RheumNow ( View Tweet)
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
Dr. John Cush RheumNow ( View Tweet)
North American Real-world EHR data of PsA & axSpA pts (n 2200 Ea.) found no higher rates of CVD (acute MI, CVA or revascularization) or solid cancers (breast, colorectal, lung, prostate) when comparing JAKi to either TNFi or IL-17i use (over 3 years). https://t.co/macjpWxdnY https://t.co/9gXiomU3YD
Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials
https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Natural RA
PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies
Features Dr. Jack Cush
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/nYhcPaC0qW https://t.co/wT80JoY4OE
Dr. John Cush RheumNow ( View Tweet)
Childhood Maltreatment and the Risk of Rheumatic Diseases
A UK retrospective matched open cohort study shows that children who suffered from abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.… https://t.co/f0XMDJbvvg https://t.co/9KvpixsNFL
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/WQCFQDnnft https://t.co/7NTNIpzEuG
Dr. John Cush RheumNow ( View Tweet)
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis (PsA).… https://t.co/yKBV91dR8z https://t.co/nndnpYheNu
Dr. John Cush RheumNow ( View Tweet)
Surveys of US IBD specialty clinic pts (n=699) used SpA screening tools ( DETAIL & IBIS-Q) finding that 27% & 40%, respectively, screened positive, mostly for axial Sxs. In screen pos pts, 31% had a prior Rheum Dx or saw a rheumatologist in the year. https://t.co/1qlAl5xVfV https://t.co/HEwdLpgx2R
Dr. John Cush RheumNow ( View Tweet)
Data from Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative & Stockholm Psoriasis Cohort (n=769 Pso Pts) finds that PsO severity (PASI) PASI assoc w/ GlycA levels (syst inflammation) & GlycA levels assoc w/ CVD risk (OR=1.23) https://t.co/IwUHILMpnI https://t.co/DnEF3yuTvg
Dr. John Cush RheumNow ( View Tweet)
Algorithm for the treatment of calcinosis #calcinosis @RheumNow #ACR24 https://t.co/NZhP7Enzrp https://t.co/1mO8waM5DI
Links:
Dr. John Cush RheumNow ( View Tweet)
